insurance coverage for glp 1 drugs Insurer strategies to control costs associated with weight loss Medicaid Coverage of and Spending

Drugs with indication and recent clinical evidence The pathophysiology of MASLD and MASH integrates insulin resistance, lipotoxicity, inflammation, and fibrogenic remodeling

This suggests that young, female, lower-weight patients may be more susceptible to IGE from GLP-1RA therapy

Inflammatory mechanisms linking obesity and tendinopathy

GLP-1 receptor agonist treatment in women with polycystic ovary syndrome-a systematic review and meta-analysis

Table 1: OVERWEIGHT, OBESITY, LIFESTYLE INTERVENTIONS AND CKD There is some evidence that lifestyle interventions to reduce weight in T2DM may be beneficial for CKD, although it is derived from a secondary analysis of a clinical trial terminated for futility

Lilly has some similar deals, but none match the scale of Novos self-pay GLP-1 pricing , now available at roughly 70,000 US pharmacies